Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene
Autor: | A. Mlynarska, T. Waszyrowski, Jarosław D. Kasprzak |
---|---|
Rok vydání: | 2006 |
Předmět: |
Male
medicine.medical_specialty Genotype Streptokinase Myocardial Infarction Stimulation Antigen Fibrinolytic Agents Polymorphism (computer science) Internal medicine Plasminogen Activator Inhibitor 1 medicine Humans Thrombolytic Therapy Myocardial infarction Allele Promoter Regions Genetic Aged Polymorphism Genetic business.industry Promoter Hematology Middle Aged medicine.disease Endocrinology Immunology Female business medicine.drug |
Zdroj: | Journal of thrombosis and haemostasis : JTH. 4(6) |
ISSN: | 1538-7933 |
Popis: | Summary. Background: Preliminary data suggest that plasma concentration of plasminogen activators inhibitor type 1 (PAI-1) is genetically determined and may be related to differential regulation of plasma PAI-1 concentration at baseline and after stimulation. Aim: This study aimed to evaluate whether increase in the plasma PAI-1 antigen concentration or activity after fibrinolytic therapy in patients with acute myocardial infarction is associated with the −675 4G/5G genetic polymorphism in the promoter region of PAI-1 gene. Results & Conclusions: Our study revealed that a rebound effect is observed in PAI-1 activity (ActPAI-1) and PAI-1 antigen (AgPAI-1) concentration after standard streptokinase treatment with maximal values of 3 h (t3) after the completion of streptokinase infusion. Both ActPAI-1 and AgPAI-1 were significantly higher at t3 compared to the levels before fibrinolytic treatment: 37.3 (20.0–67.7) vs. 10.0 (3.6–26.0) IU L−1; P = 0.00001 and 29.9 (15.6–42.3) vs. 20.9 (13.0–30.2) ng mL−1; P = 0.001, respectively. The stratification of the patients by genotype revealed that carriers of the 4G allele had higher concentrations of PAI-1 antigen 3 h after streptokinase infusion: 30.9 vs. 13.8 ng mL−1; P = 0.019. No significant association between PAI-1 activity and genotype was found. In conclusion, the rebound effect in serum PAI-1 concentration observed after streptokinase treatment may be related to the 4G/5G polymorphism in the PAI-1 gene promoter. |
Databáze: | OpenAIRE |
Externí odkaz: |